The Latest Breaking News from the Food and Drug Administration

Drugmaker Lykos Therapeutics announced on Aug. 9, 2024, that the Food and Drug Administration declined to approve the company’s application for the use of MDMA-assisted therapy in the treatment of post-traumatic stress disorder. It is the first such decision issued on a psychedelic drug application.

The Food and Drug Administration declined to approve MDMA as the first psychedelic drug used to treat post-traumatic stress disorder.

Omega-3 is known for cognitive advantages like improving brain development, enhancing mental performance, and lowering the risk of neurodegenerative disorders.

As bird flu spreads through US cattle, a hip California grocery store is making a smoothie from unpasteurized dairy and a supplement made from organs

The FDA announced that it would be rescinding its action against Juul due to new case law and the agency’s review of information

Clinical trials of MDMA have been promising, but concerns have emerged about the quality of the research. A June hearing scheduled by the Food and Drug Administration is likely to address them.

It is unclear why the suggested rule was not released by its intended deadline. But a spokesperson for the federal agency told NPR that its implementation "continues to be a high priority."

Officially, only one person has caught the illness during the current outbreak. But with limited testing, cases could be flying under the radar.

The FDA found last week one in five commercial milk samples surveyed contained remnants of the H5N1 virus